Last reviewed · How we verify
Lendorm (BROTIZOLAM)
At a glance
| Generic name | BROTIZOLAM |
|---|---|
| Drug class | brotizolam |
| Target | Platelet-activating factor receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1984 |
Approved indications
Common side effects
Key clinical trials
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients. (PHASE3)
- Treatment With Benzodiazepine After Cardiac Surgery (PHASE3)
- Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults (PHASE1,PHASE2)
- Lendormin D® Tablet (Drug Use Result Survey)
- Pharmacological Study on Absorption of WE 941 OD Tablets in Japanese Healthy Male Volunteers (PHASE1)
- Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) Taken With Water in Healthy Adult Males (PHASE1)
- Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lendorm CI brief — competitive landscape report
- Lendorm updates RSS · CI watch RSS